

# NIH Public Access

Author Manuscript

Disabil Rehabil. Author manuscript; available in PMC 2012 January 1.

# Published in final edited form as:

Disabil Rehabil. 2011; 33(7): 589–598. doi:10.3109/09638288.2010.503256.

# Measuring Substantial Reduction in Functioning in Patients with CFS

Leonard A. Jason, Molly Brown, Meredyth Evans, Valerie Anderson, Athena Lerch, Abigail Brown, Jessica Hunnell, and Nicole Porter DePaul University

# Abstract

**Purpose**—All of the major current case definitions for chronic fatigue syndrome (CFS) specify substantial reductions in previous levels of occupational, educational, social, or personal activities to meet criteria. Difficulties have been encountered in operationalizing "substantial reductions." For example, the Medical Outcomes Study Short Form-36 Health Survey (SF-36) has been used to determine whether individuals met the CFS disability criterion. However, previous methods of using the SF-36 have been prone to including people without substantial reductions in key areas of physical functioning when diagnosing CFS. This study sought to empirically identify the most appropriate SF-36 subscales for measuring substantial reductions in patients with CFS.

**Method**—The SF-36 was administered to two samples of patients with CFS: one recruited from tertiary care and the other a community-based sample; as well as a non-fatigued control group. Receiver operating characteristics were used to determine optimal cutoff scores for identifying patients with CFS.

**Results**—The SF-36 Role-Emotional subscale had the worst sensitivity and specificity, whereas the Vitality, Role-Physical, and Social Functioning subscales had the best sensitivity and specificity.

**Conclusion**—Based on evidence from this study, potential criteria for defining substantial reductions in functioning and diagnosing CFS is provided.

# Introduction

Chronic fatigue syndrome (CFS) is a poorly understood illness lacking a clearly defined etiology. Current case definitions of CFS are vaguely worded and not operationalized. Consequently, the reliability of the diagnostic criteria is at risk, potentially leading to differences in CFS samples across research studies. An important component of CFS diagnostic criteria that has not been well-defined is level of disability. Specifically, to diagnose CFS using the Fukuda et al. [1] criteria, it is important to assess substantial reductions in "previous levels of occupational, educational, social, or personal activities" [1, p. 956]. Objective measures of activity may be an advantageous approach to assessing this substantial reductions construct compared to self-report measures. However, for research purposes, subjective measures may be more desirable for screening this construct due to ease of administration and lower cost. An instrument that has been frequently used to assess substantial reductions is the Medical Outcomes Study Short Form-36 Health Survey (SF-36)

#### **Declarations of Interest**

Correspondence concerning this article should be addressed to Leonard A. Jason, Ph.D., Director, Center for Community Research, 990 W. Fullerton Ave., Suite 3100, Chicago, II. 60614. telephone: 773-325-2018; fax: 773-325-4923; Ljason@depaul.edu.

The authors appreciate the financial assistance provided by the National Institute of Allergy and Infectious Diseases (grant numbers AI36295 and AI055735).

[2]. This instrument is a 36-item, broadly-based, self report measure of functional status related to physical functioning, role physical functioning, role emotional functioning, social functioning, bodily pain, general health, vitality, and mental health. Higher scores on this scale indicate better functioning. The SF-36 has been recommended by several groups, including Reeves et al. [3] to assess substantial reductions in previous levels of occupational, educational, social, and personal activities.

Reeves et al.'s [4] empiric CFS case definition attempted to operationalize the substantial reductions construct using the SF-36. According to this empiric CFS case definition, the CFS disability criterion would be met by scoring at or below the 25<sup>th</sup> percentile on any one of the following four SF-36 subscales: Physical Functioning (less than or equal to 70), Role-Physical (less than or equal to 50), Social Functioning (less than or equal to 75), or Role-Emotional (less than or equal to 66.7). Jason et al. [5] have questioned the inclusion of the Role-Emotional subscale because a person could meet the disability CFS criterion without any reductions in key areas of physical functioning, and only have impairment in role emotional areas (e.g., problems with work or other daily activities as a result of emotional problems). Ware et al. [2] found that the mean for Role-Emotional for a clinical depression group was 38.9, indicating that almost all those with clinical depression would meet the CFS disability criterion, as they would be within the lower 25<sup>th</sup> percentile on this subscale.

Rather than arbitrarily selecting the lower 25% for four SF-36 subscales, as was recommended in Reeves et al.'s [4] empiric CFS case definition, the present study first examined the use of the SF-36 in the existing literature to determine which subscales best differentiated CFS and control groups. We next used Receiver Operating Characteristics (ROC) to determine which subscales best discriminate between patients with CFS versus controls who are not ill. Given that substantial reductions in functioning are only one criterion used to diagnose CFS and can occur in several medical and psychological illnesses, this measure alone would not suffice in differentiating CFS from other conditions. Therefore, the objective of this study was to determine the level of reductions necessary to differentiate patients with CFS from those who are not ill, as well as to examine which SF-36 subscales are optimal in making this distinction. In order to increase the generalizability of our findings, we used two CFS samples: a tertiary care sample and a community-based sample. In addition, we determined cutoff points on the most discriminating subscales with the best sensitivity and specificity. These cutoff points were subsequently used in a final ROC to determine how many subscale cutoffs needed to be met to best differentiate the CFS groups from the controls.

## Methods

#### Literature review

Because of the importance of the SF-36 for CFS diagnostic purposes, it is useful to review the findings of CFS investigators using this scale. The authors searched for peer-reviewed articles in the following major online databases: PsycInfo, PubMed, and Google Scholar. Search terms included: chronic fatigue syndrome, Myalgic Encephalomyelitis, SF-36, MOS SF-36, Medical Outcome Study Short Form 36 Health Survey, and substantial reductions. Within this search strategy, articles included in Table 1 reported means, standard deviations, and/or confidence intervals of SF-36 subscale scores. Further, studies were included if they used one or more comparison group or subgroups of patients with CFS. Thus, this is not an exhaustive literature review but rather a representation of literature on SF-36 scores among patients with CFS. A total of 17 studies were found that included CFS samples and used the SF-36. Descriptive statistics were obtained for the SF-36 subscales. Nine of the 17 studies had a CFS and non-ill control group, and these studies were used to compare SF-36 subscale scores were

averaged for the CFS groups, and, separately, the control groups. Differences between the CFS and control group means were computed for each of the subscales.

#### **Community-based sample**

The data for the community-based CFS sample and the controls in the present investigation were derived from a larger community-based study of the prevalence of CFS [6]. This larger study was carried out in three stages. Stage 1 involved administering an initial telephone screening questionnaire in order to assess for symptoms of CFS. Procedures developed by Kish [7] were used to select one adult from each household. Birth dates for each adult were gathered, and the person with the most recent birthday was selected to be interviewed. We screened a random sample of adults (aged 18 years or older) between September 1995 and May 1997. A stratified random sample of several neighborhoods in Chicago, which were 10–15 minutes from the site of the medical examinations, was utilized. We called 28,673 residential/working telephone numbers and were able to complete the interview for 18,675 adults (65.1% completion rate). If interviewees reported during the stage 1 interview that they had been suffering from severe fatigue, extreme tiredness, or exhaustion that had been present for a period of six months or longer, they were determined to have chronic fatigue and were asked additional questions which assessed more specific dimensions of their fatigue.

The stage 1 screen revealed that of the 18,675 interviewees, 780 (4.2%) had chronic fatigue. Of these, 408 reported chronic fatigue and the concurrent occurrence of four or more of the core symptoms listed in the Fukuda et al. [1] CFS case definition, and they were defined as CFS-like. The suffix 'like' was used to clarify that individuals in this group only met criteria by self-report, and thus did not necessarily qualify as having a final diagnosis of CFS rendered by physician evaluation.

Stage 2 involved administering a semi-structured psychiatric interview, and stage 3 involved administering a complete physical examination (see Jason et al. [6] for more details). There were 166 of the 408 CFS-like individuals who agreed to complete a structured psychiatric interview in stage 2 and also agreed to undergo a complete physical examination in stage 3. There were no significant differences on sociodemographic or fatigue scores between those 166 screened positive (CFS-like) participants and the 242 screened positive (CFS-like) non-participants.

A team of four physicians and a psychiatrist were responsible for making final diagnoses. Two physicians independently rated each file using the Fukuda et al. [1] criteria for CFS. If a disagreement occurred, a third physician rater was used. Each of the 166 CFS-like participants evaluated in stages 2 and 3 was diagnosed by the physician review panel in one of three ways: (1) individuals evaluated as meeting the Fukuda et al. criteria for CFS were given a final diagnosis of CFS (n = 32); (2) individuals not meeting full CFS criteria, but possessing unexplained chronic fatigue and no exclusionary medical conditions detected in evaluation were given a final diagnosis of idiopathic chronic fatigue (ICF; n = 45); and (3) individuals with exclusionary medical or psychiatric conditions detected in evaluation were given a final diagnosis of CF-explained (n = 89). The 32 individuals who met criteria for CFS were used in the present investigation for the community-based CFS sample.

The control group was composed of individuals selected randomly from those 18,260 screened negatives (groups included participants with no reported prolonged or chronic fatigue). Among the 199 controls randomly selected for evaluation following Stage 1, the physician review team identified 47 individuals who were medically worked up and found not to have CFS. This control group was used for comparison with both the community-

based CFS sample and the tertiary care CFS sample in the present study. See Jason et al. [6] for more details regarding recruitment and procedure.

Regarding sociodemographic characteristics, of the 32 individuals with CFS, 71.9% were women. In terms of ethnicity, 46.9% were Caucasian, 28.1% were Latino, 15.6% were African American, and 9.4% were of another ethnicity. Among the CFS group, 40.6% were married, 62.5% had children, 53.1% were working either full time or part time, 84.4% had at least a high school diploma or higher education, 75.0% were at least at the occupational level of a skilled or clerical worker and higher, and the average age was 40.8.

Of the 47 controls, 48.8% were women. In terms of ethnicity 58.1% were Caucasian, 27.9% were African American, 7.0% were Latino, and 7.0% were of another ethnicity. Among the control group, 27.9% were married, 27.9% had children, 81.4% were working either full time or part time, 93.0% had at least a high school diploma or higher education, 83.7% were at least at the occupational level of a skilled or clerical worker and higher, and the average age was 41.5.

With respect to gender, significantly higher frequencies of females than males were observed in CFS than in the control group. In terms of work status, a significantly higher number of individuals in the control group reported working full-time when compared with individuals in CFS group, who were more likely to be unemployed, on disability, or working part-time. Individuals in CFS and control groups did not differ significantly with respect to racial/ethnic identification, age, and marital status.

#### Tertiary care sample

The data for the tertiary care CFS sample in the present investigation were baseline data derived from a larger non-pharmacological interventions study for CFS [8]. Participants were recruited from a variety of sources including physician referrals, newspaper advertisements, and CFS support groups. All participants were required to be at least 18 years of age, not pregnant, able to read and speak English, and considered to be physically capable of attending the scheduled sessions.

A semi-structured psychiatric interview (the Structured Clinical Interview for DSM-IV) [9] was administered to establish Axis I psychiatric diagnoses and rule out exclusionary psychiatric diagnoses according to the Fukuda et al. [1] criteria. Next, an in-depth medical and laboratory evaluation similar to that which was given in the community-based sample was conducted (see Jason et al. [8] for more details). One hundred and fourteen individuals were diagnosed with CFS based on the Fukuda et al. [1] criteria and enrolled in the study. See Jason et al. [8] for more details regarding recruitment and procedure.

In regards to sociodemographic characteristics, 83.3% of the 114 participants were female and the average age was 43.8 years (standard deviation = 11.6). Concerning ethnicity, 87.7% of the participants were White, 4.4% were African American, 4.4% were Latino, and 3.5% were Asian American. Regarding marital status, 49.1% of the participants were married/ living with a partner, 33.3% were single, and 17.6% were either divorced or separated. As for work status, 40.4% of the participants were working or full-time students, and 59.6% were not working or were part-time students. Concerning education, 47.4% of the participants had earned a standard college degree, 21.8% had a graduate or professional degree, 21.1% had partial college, and 9.7% had a high school/GED degree or less.

#### Measure

CFS and control participants in the community-based study and CFS participants in the tertiary care study completed the SF-36 [2], a reliable and valid measure that discriminates

between gradations of disability. This measure includes eight subscales measuring various aspects of disability: Physical Functioning, Social Functioning, Role-Physical, Role-Emotional, Vitality, Bodily Pain, General Health, and Mental Health. Scores on each subscale range from 0 to 100, with higher scores indicating better health or functioning. Reliability and validity studies for the SF-36 have shown adequate internal consistency, discriminant validity among subscales, and substantial differences between patient and nonpatient populations in the pattern of scores [10,11].

#### Statistical analysis

The statistical software package used for data analysis was PASW (formerly SPSS) for Windows, version 17.0. A Receiver Operating Characteristic (ROC) curve analysis [12] was used to evaluate the ability of the SF-36 subscales to discriminate between patients with CFS in the community-based sample and controls, and between those in the tertiary care sample and the same controls. The ROC curve graphically represents the probability of true positive results in diagnosis as a function of the probability of false positive results of this test. Sensitivity is defined as the probability that the test correctly classifies a CFS subject as positive. A true positive is defined as a participant who scores positive on the SF-36 subscale test for CFS and actually has the illness, whereas a false positive occurs when a participant whose SF-36 subscale tests positive for CFS but the person does not have the illness. Specificity involves a test correctly classifying a non-ill participant as negative. A true negative is defined as a participant who tests negative on the SF-36 subscale test for CFS and does not have the illness, whereas a false negative is defined as a participant who tests negative on the SF-36 subscale test for CFS and actually has the illness.

An ROC analysis is produced by plotting the sensitivity versus 1 - specificity for all cutoff points of the SF-36 subscales. The area under the curve (AUC) is an indicator of the discriminatory ability of the scale: a straight line (area = 0.5) means that the scale is doing no better than chance in classifying CFS and non-CFS, while a perfect scale would have an ROC curve with an area of 1. The area under the ROC curve is a summary measure that essentially averages diagnostic accuracy across the spectrum of test values. The informative area under the ROC curve ranges from 0.5 to 1.0, and not from 0.0 to 1.0, as would the area under a probability distribution curve. An AUC of 0.99 means that 99% of the time a randomly selected individual from the CFS group will more adequately fulfill the SF-36 subscale criterion than a randomly selected individual from the control group.

# Results

#### Literature review

Table 1 lists the 17 studies that used the SF-36 in CFS studies with at least two comparison groups. Of these, the nine studies used to calculate difference scores are noted in table 1. Differences between the CFS and non-ill control groups were: 70.1 for Role-Physical; 48.7 for Vitality; 46.0 for Social Functioning; 41.5 for Physical Functioning; 38.5 for Bodily Pain; 38.4 for General Health; 30.9 for Role-Emotional; and 20.9 for Mental Health. These findings suggest that Role-Physical is clearly the best discriminator between CFS and controls, with the next groups being Vitality, Social Functioning, Physical Functioning, Bodily Pain, and General Health; and dimensions that showed the least discrimination between the CFS and control groups were Role-Emotional and Mental Health.

#### **ROC** analyses

Table 2 presents data on the AUC, standard error, and 95% confidence intervals. A test needs an AUC threshold of between 90–100% to have diagnostic meaning [28,29]. For the community-based sample, none of the scales had an AUC above 0.90, although Vitality,

Role-Physical, and Social Functioning had 0.86 or above AUC. For the tertiary care CFS sample, three subscales had an AUC of 0.91, and they included Vitality, Role-Physical, and General Health. Physical Functioning and Social Functioning had an AUC of 0.87. Only Vitality, Social Functioning, and Role-Physical emerged as within the top 4 for each sample. For both samples, Role-Emotional and Mental Health had the lowest thresholds, similar to what had been found in the literature review from table 1. From these findings, taking into consideration both samples, it appears that Vitality, Social Functioning, and Role-Physical are among the highest AUCs for both samples. Given these findings, there is an argument for focusing on only those three subscales with the highest AUC thresholds (Vitality, Social Functioning, and Role-Physical).

We next focused on optimal cutoff points for these two subscales. For Vitality, a score of 35 or less in the community-based sample had 90% sensitivity and 81% specificity; whereas in the tertiary care sample, a score of 35 or less had 89% sensitivity and 81% specificity. For Social Functioning, a score of 62.5 or less in the community-based sample had 87% sensitivity and 72% specificity; whereas in the tertiary care sample, a score of 62.5 or less had 88% sensitivity and 72% specificity. For the Role-Physical subscale, a score of 50 or less had 97% sensitivity and 70% specificity for the community-based sample; whereas for the tertiary care sample, a score of 25 or less had 96% sensitivity and 79% specificity (there are only 4 items on this scale, so a person can only get a score of 0, 25, 50 or 100). Based on these findings, we used a cut-off score of  $\leq$  35 or less for Vitality,  $\leq$  62.5 for Social Functioning, and  $\leq$  50 for Role-Physical.

As it is unclear if the optimal diagnosis for CFS would require a person to meet the cutoff for one or more subscales (i.e.,  $\leq 35$  on Vitality,  $\leq 62.5$  on Social Functioning, and/or  $\leq 50$ on Role-Physical), we conducted ROCs examining the total number of scales met by participants (range 0 to 3). For the community-based sample, the ROC resulted in an AUC of 0.89 (SE = 0.04, 95% CI 0.82 to .96, p < 0.001). If the person met the cutoff for one or more subscales, the sensitivity was 100% and the specificity was 64%. If the person met the cutoff for two or more subscales, the sensitivity was 93% and the specificity was 75%. If the person met the cutoff for three subscales, the sensitivity was 79% and the specificity was 85%.

For the tertiary care sample, the ROC resulted in an AUC of 0.90 (SE = 0.03, 95% CI 0.83 to .96, p < 0.001). If the person met the cutoff for one or more subscales, the sensitivity was 100% and the specificity was 64%. If the person met the cutoff for two or more subscales, the sensitivity was 96% and the specificity was 75%. If the person met the cutoff for three subscales, the sensitivity was 81% and the specificity was 85%.

If investigators are attempting to identify as many as possible cases of CFS from either community-based or tertiary care samples, then higher sensitivity is better. Even though specificity might be lower, when a medical and psychiatric examination is conducted, those individuals who have other fatigue-causing medical or psychiatric conditions would be excluded from the CFS samples. Therefore, we would recommend that meeting two or more of the following three subscales: Vitality, Social Functioning, or Role-Physical, with our designated cutoff scores, should be used to designate substantial reductions.

### Discussion

Although the SF-36 [2] has been recommended as a good measure to achieve the goal of determining substantial reductions in functioning [3], it is important for a measure assess reductions in functioning to have high sensitivity by identifying the majority positive CFS cases, while also having high specificity to successfully identify non-ill cases.

Unfortunately, few studies have used rigorous statistical methods to determine which variables and cutoff scores to use to assess substantial reductions in functioning among people with CFS. The present study found that the SF-36 Vitality, Social Functioning, and Role-Physical subscales have the best sensitivity and specificity using two different samples of individuals with CFS. The Vitality scale measures items that assess feeling full of pep and energy, as well as those that focus on feeling worn out or tired. Social functioning is assessed by items that involve interference with normal social activities with family, friends, neighbors, or groups. The Role-Physical subscale focuses on items assessing the need to cut down on or limit work or other activities, as well as accomplishing less than one might like. In other words, these three subscales capture significant limitations in the person's energy level, involvement in social activities, and life accomplishments. Of interest, these subscales not only had the best AUC thresholds, but in Table 1, they were the subscales that had the largest difference scores between CFS and control groups. These three subscales might assess substantial reductions in "previous levels of occupational, educational, social, or personal activities" [1, p. 956].

Reeves et al.'s [4] empiric CFS case definition recommended using scores below the 25<sup>th</sup> percentile on any one of the following four SF-36 subscales to measure disability: Physical Functioning (less than or equal to 70), Role-Physical (less than or equal to 50), Social Functioning (less than or equal to 75), or Role-Emotional (less than or equal to 66.7). If a person met the criteria for Role-Emotional functioning, and did not meet any other criteria, they would meet the CFS disability criteria for the case definition. The literature review outlined in table 1 indicates that among the different subscales, the CFS versus non-ill control groups have among the least difference for the Role-Emotional subscale. In a study by Jason et al. [16] (See table 1), the mean Role-Emotional score for the chronic fatigue psychiatric exclusion group was 25.6 (SD = 34.7) versus 45.2 (SD = 45.6) for the CFS group. Therefore, using Reeves et al.'s Role-Emotional cutoff of less than or equal to 66.7 would select the majority of those with chronic fatigue explained by psychiatric reasons as meeting the CFS disability criterion. In addition, Jason et al. [5] found that almost all of those with clinical depression would meet the CFS disability criterion, and this is in part due to the inclusion of the Role-Emotional subscale. Furthermore, the AUC for the Role-Emotional subscale was the worst among the eight SF-36 subscales in table 2 for discriminating patients with CFS from controls.

It could be argued from both tables 1 and 2 that other SF-36 scales have somewhat good discrimination between the CFS and control groups including Physical Functioning, Bodily Pain, and General Health. Physical Functioning was also a subscale recommended for inclusion by Reeves et al. [1]. When we examined the cutoff score to select 90% of CFS cases for Physical Functioning, a very high score would be needed ( $\leq 85$ ) and this would have poor specificity (62%). Within the data set described by Jason et al. [16], it is only with items assessing more vigorous activities that a separation occurs between those with CFS and those who are chronically fatigued due to psychiatric reasons. When examining the raw scores of the individual items comprising the Physical Functioning subscale, on relatively non-strenuous activities (e.g., bathing or walking one block), there are no significant differences between the CFS group and the control group. As the intensity of the activity increases, both fatigued groups become significantly differentiated from the control group. However, it is only for "walking more than one mile" that the CFS group demonstrates greater functional impairment than the chronic fatigue explained by psychiatric reasons group.

We considered both Bodily Pain as well as General Health beyond the scope of what was to be measured to represent substantial reductions in occupational, educational, social, or personal functioning. In addition, the cutoff for Bodily Pain ( $\leq$  74) to detect 90% of CFS

cases in the tertiary care sample had a poor specificity (66%). In addition, a major problem with the General Health subscale was that for the community-based sample, to accurately select 90% of CFS cases, an extremely high cut off score would be needed ( $\leq 80$ ) and this score would have very poor specificity (53%).

The reason for using a tertiary care and community-based sample was to assess whether comparable findings would emerge with the two different samples. As shown in table 2, the community-based sample had, in general, lower AUCs than the tertiary care sample. The difference in AUCs suggests that the community-based sample was less accurately discriminated from controls than was the tertiary care sample. In CFS research, it has been found that participants recruited from the community tend to be less impaired than those recruited from tertiary care settings [30]. It is likely that our tertiary care sample was more impaired, making them more distinguishable from controls on the SF-36 subscales.

There are several limitations in this study. First, the community-based sample of participants was relatively small. In addition, there was only one control group, and it was used to contrast two different samples of individuals with CFS. In addition, our study recommends using three subscales of the SF-36, but some might argue that more subscales need to be included to provide a more comprehensive appraisal of reduced functioning. Finally, we only tested substantial reductions on self-report measures of functional disability, and there might be other more objective approaches that are worthy of consideration, including those measuring either activity, such as actigraphs [31], or more biological variables, such as Orthostatic Intolerance [32]. However, objective measures of activity can be costly, difficult to administer, and involve a greater burden on participants than completing a self-report measure. The SF-36 proved to be useful in operationalizing substantial reductions for research purposes.

In summary, our study suggests that three subscales of the SF-36 could be used to assess substantial reductions in different areas of functioning, as these scales have the best sensitivity and specificity across two CFS samples, and have demonstrated the largest discrimination between CFS and control groups in previous studies. It is hoped that future studies will assess whether these three subscales are effective in documenting substantial reductions in functioning in other CFS samples. Clearly, great care needs to be exercised when determining which scales and with what cutoff points should indicate that substantial reductions CFS criterion has been reached for CFS samples in order to identify true CFS cases.

### Acknowledgments

The authors appreciate the financial assistance provided by the National Institute of Allergy and Infectious Diseases (grant number AI055735).

#### References

- Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994; 121:953– 959. [PubMed: 7978722]
- 2. Ware, JE.; Snow, KK.; Kosinski, M. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: Quality Metric Inc; 2000.
- Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason L, Bleijenberg G, Evengard B, White PD, Nisenbaum R, Unger ER. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Services Research. 2003; 3:25. [PubMed: 14702202]

- Reeves, WC.; Wagner, D.; Nisenbaum, R.; Jones, JF.; Gurbaxani, B.; Solomon, L.; Papanicolaou, D.; Unger, ER.; Vernon, SD.; Heim, C. Chronic fatigue syndrome – a clinical empirical approach to its definition and study; BMC Medicine. 2005. p. 19(available at: http://www.biomedcentral.com/content/pdf/1741-7015-3-19.pdf)
- Jason LA, Najar N, Porter N, Reh C. Evaluating the centres for disease control's empirical chronic fatigue syndrome case definition. J Disabil Policy Stud. 2009; 20:93– 100.10.1177/1044207308325995
- Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang C, Plioplys S. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999; 159:2129–2137. [PubMed: 10527290]
- 7. Kish, L. Survey Sampling. NY: Wiley; 1965.
- Jason LA, Torres-Harding S, Friedberg F, Corradi K, Njoku MG, Donalek J, Reynolds N, Brown M, Weitner BB, Rademaker A, Papernik M. Non-pharmacologic interventions for CFS: a randomized trial. J Clin Psychol Med Settings. 2007; 14:275–296.
- Spitzer, RL.; Williams, JBW.; Gibbon, M.; First, MB. Structured Clinical Interview for the DSM-IV —non-patient edition (SCID—NP, Version 2.0). Washington, DC: American Psychiatric Press; 1995.
- McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31:247–263. [PubMed: 8450681]
- McHorney CA, Ware JE, Lu AW, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32:40–66. [PubMed: 8277801]
- Hanley JA, Mc Neil BJ. The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology. 1982; 143:29–36. [PubMed: 7063747]
- Boneva RS, Decker MJ, Maloney EM, Lin J, Jones JF, Helgason HG, Heim CM, Rye DB, Reeves WC. Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: A population-based study. Autonomic Neuroscience: Basic and Clinical. 2007; 137:94– 101.
- Ciccone DS, Busichio K, Vickroy M, Natelson BH. Psychiatric morbidity in the chronic fatigue syndrome: are patients with personality disorder more physically impaired? J Psychosom Res. 2003; 54:445–452. [PubMed: 12726901]
- Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin Immunol and Immuopathol. 1998; 87:60–67.
- Jason LA, King CP, Taylor RR, Kennedy C. Defining chronic fatigue syndrome: methodological challenges. J Chronic Fatigue Syndr. 2000; 7:17–32.
- King C, Jason L. Improving the diagnostic criteria and procedures for chronic fatigue syndrome. Biol Psychol. 2005; 68:87–106. [PubMed: 15450690]
- Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, Kornish J, Ware NC, Ware JE, Bates DW. Health status in patients with chronic fatigue syndrome and in general population ad disease comparison groups. Am J Med. 1996; 101:281–290. [PubMed: 8873490]
- Moss-Morris R, Chalder T. Illness perceptions and levels of disability in patients with chronic fatigue syndrome and rheumatoid arthritis. J Psychosom Res. 2003; 55:305–308. [PubMed: 14507540]
- 20. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res. 1999; 8:9–16. [PubMed: 10457734]
- Nijs J, Almond F, Becker PD, Truijen S, Paul L. Can exercise limits prevent post-exertional malaise in chronic fatigue syndrome? An uncontrolled clinical trial. Clin Rehabil. 2008; 22:426– 435. [PubMed: 18441039]
- Nijs J, Thielemans A. Kinesiophobia and symptomatology in chronic fatigue syndrome: A psychometric study of two questionnaires. Psychol Psychother. 2008; 81:273–283. [PubMed: 18644213]

- Scheeres K, Wensing M, Severens H, Adang E, Bleijenberg G. Determinants of health care use in chronic fatigue syndrome patients: a cross-sectional study. J Psychosom Res. 2008; 65:39–46. [PubMed: 18582610]
- 24. Taillefer SS, Kirmayer LJ, Robbins JM, Lasry J. Psychological correlates of functional status in chronic fatigue syndrome. J Psychosom Res. 2002; 53:1097–1106. [PubMed: 12479992]
- Herrell R, Goldberg J, Hartman S, Belcourt M, Schmaling K, Buchwald D. Chronic fatigue and chronic fatigue syndrome: A co-twin control study of functional status. Quality of Life Research. 2002; 11:463–471. [PubMed: 12113393]
- Nater UM, Wagner D, Solomon L, Jones JF, Unger ER, Papanicolaou DA, Reeves WC, Heim C. Coping styles in people with chronic fatigue syndrome identified from the general population of Wichita, KS. J Psychosom Res. 2006; 60:567–573. [PubMed: 16731231]
- Wells DL. Associations between pet ownership and self-reported health status in people suffering from chronic fatigue syndrome. J Altern Complement Med. 2009; 15:407–413. [PubMed: 19388863]
- Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007; 115:654–657. [PubMed: 17283280]
- 29. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993; 39:561–577. [PubMed: 8472349]
- Jason LA, Plioplys AV, Torres-Harding S, Corradi K. Comparing symptoms of chronic fatigue syndrome in a community-based versus tertiary care sample. J Health Psychol. 2003; 8:459–464. [PubMed: 19127712]
- Tryon WW, Jason LA, Frankenberry E, Torres-Harding S. Chronic fatigue syndrome impairs circadian rhythm of activity level. Physiology & Behavior. 2004; 82:849–53. [PubMed: 15451649]
- Streeten DH, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci. 2000; 320:1–8. [PubMed: 10910366]

**NIH-PA** Author Manuscript

**NIH-PA** Author Manuscript

ble 1
Ta

gnosis
Diag
a CFS
with
dividuals
or Inc
Scores f
SF-36
Reporting 5
Studies
from
Results
of ]
Summary

Study	Population	a	Role-Phys. M (SD)	Physical Func. M (SD)	Vitality M (SD)	Social Func. M (SD)	Bodily Pain M (SD)	Role-Emo. M (SD)	Ment. Health M (SD)	Gen. Health M (SD)
Boneva et al. (2007) $\dot{t}$	CFS	30	23.3 (32.1)	55.0 (21.5)	18.5 (12.2)	50.8 (23.7)	42.1 (17.1)	NR	64.4 (20.0)	52.9 (21.3)
	Control	38	85.5 (28.3)	90.1 (12.0)	70.8 (14.3)	94.7 (10.7)	77.7 (17.8)	NR	86.4 (8.9)	83.2 (15.2)
Ciccone, Busichio, Vickroy, &	CFS	24	17.7 (34.2)	41.7 (18.6)	17.7 (18.4)	42.7 (22.7)	36.0 (23.5)	80.6 (35.3)	78.8 (12.9)	38.6 (25.0)
Natelson (2003)	CFS w/Psy	27	5.6 (14.4)	40.6 (22.3)	15.0 (12.9)	37.5 (23.0)	28.9 (18.3)	50.6 (51.8)	60.1 (19.0)	32.1 (13.1)
	CFS w/Personality Disorder	21	16.7 (28.9)	45.0 (27.2)	12.6 (11.7)	45.2 (33.2)	38.7 (22.9)	69.8 (68.2)	55.0 (18.7)	27.4 (15.8)
Hassan, Bannister, Akbar, Weir,	CFS	44	10.2 (19.7)	29.1 (16.4)	11.9 (13.3)	30.1 (21.6)	32.6 (19.7)	68.9 (42.2)	66.6 (18.4)	25.7 (13.4)
& Bofill $(1998)^{T}$	Control	20	91.3 (23.3)	94.8 (6.9)	69.3 (20.2)	91.1 (14.2)	88.3 (12.7)	85.0 (29.6)	77.6 (16.4)	79.4 (18.9)
Jason, King, Taylor, & Kennedy	CFS	32	18.1 (23.3)	51.6 (23.3)	24.2 (13.6)	44.9 (19.4)	39.7 (24.8)	45.2 (45.6)	56.3 (21.3)	47.8 (24.7)
$(2000)^{T}$	Psy Exclusion	56	28.3 (37.6)	59.1 (28.0)	33.0 (19.0)	46.6 (23.6)	53.7 (25.3)	25.6 (34.7)	47.5 (21.3)	49.9 (21.3)
	Control	47	77.3 (37.3)	87.6 (24.0)	64.2 (24.9)	82.9 (26.5)	80.9 (27.3)	76.2 (39.2)	77.4 (18.3)	77.3 (20.3)
Jason et al. (2009) <sup>*</sup> , <i>a</i>	CFS	27	5.6 (16.0)	37.4 (23.4)	NR	30.1 (28.4)	NR	69.1 (40.2)	NR	NR
	MDD/CFS	14	51.8 (41.0)	70.4 (32.9)	NR	42.0 (23.3)	NR	19.1 (31.3)	NR	NR
	MDD	23	58.7 (45.6)	76.7 (21.3)	NR	40.2 (25.3)	NR	30.4 (40.1)	NR	NR
King & Jason $(2005)^{\ddagger}$	CFS	15	13.3	44.0	14.0	35.0	38.5	48.9	39.3	31.6
	MDD	15	44.3	70.3	44.0	60.8	55.6	37.8	39.1	49.9
	Control	15	90.0	88.0	66.7	90.8	76.3	91.1	79.7	66.7
Komaroff et al. (1996) $^{\ddagger}$	CFS	223	17.1 (30.7)	54.5 (25.9)	25.7 (21.0)	45.8 (26.2)	49.7 (25.4)	62.9 (42.0)	62.1 (20.6)	33.8 (19.4)
	Control	2474	81.0 (34.0)	84.2 (23.3)	60.9 (21.0)	83.3 (22.7)	75.2 (23.7)	81.3 (33.0)	74.7 (18.0)	72.0 (20.3)
Moss-Morris & Chalder (2003)	CFS	49	1.45 (.07)	43.7 (3.7)	20.9 (3.0)	41.7 (3.9)	NR	NR	65.5 (3.0)	NR
	Rheumatoid Arthritis	75	1.82 (.05)	41.9 (2.9)	44.4 (2.6)	62.9 (3.1)	NR	NR	66.9 (2.6)	NR
Myers & Wilks (1999) $\dot{\vec{r}}$	CFS	85	21.2 (34.4)	52.4 (31.0)	27.2 (22.3)	49.3 (28.1)	50.9 (29.5)	60.0 (43.9)	61.8 (21.8)	39.8 (21.9)
	Control	9332	91.4 (23.2)	92.5 (13.4)	64.0 (18.2)	91.3 (15.8)	86.3 (17.9)	85.6 (29.3)	75.4 (16.3)	78.8 (15.7)
Nijs, Almond,	CFS Pre-Exerc.	24	22.9 (32.9)	52.5 (21.2)	40.6 (17.2)	51.0 (23.3)	60.4 (22.0)	70.7 (42.2)	55.5 (17.5)	25.0 (12.1)
Becker, Truijen, & Paul (2008) $^{b}$	CFS Post-Exerc.	24	18.8 (28.8)	49.8 (19.6)	36.3 (13.7)	47.4 (20.8)	55.6 (22.2)	58.3 (43.1)	56.8 (17.3)	25.4 (12.9)
	CFS 24 Hours-Post	23	16.3 (26.8)	50.7 (20.1)	36.5 (12.7)	48.9 (18.0)	55.3 (20.3)	63.8 (41.3)	57.7 (13.9)	27.8 (14.6)
Nijs & Thielemans (2008) <sup>c</sup>	CFS Dutch	100	14.5 (26.4)	50.6 (22.1)	36.1 (19.2)	43.5 (23.2)	41.0 (22.0)	58.7 (45.7)	57.6 (21.3)	21.2 (13.7)
	CFS French	48	20.3 (31.7)	46.0 (24.0)	22.1 (22.6)	38.5 (24.2)	31.4 (22.3)	45.8 (43.3)	49.8 (21.4)	20.0 (12.5)
Reeves et al. $(2005)^{\ddagger}$ *	CFS	43	18.0 (28.5)	53.3 (21.5)	18.6 (12.5)	50.0 (22.7)	41.7 (15.7)	55.8 (42.2)	66.4 (18.5)	51.2 (20.4)

_
-
_
<u> </u>
_
$\sim$
()
_
_
-
-
Ē.
Ĩ,
<sup>r</sup>
Š
Ň
r Ma
r Ma
r Ma
r Mar
r Man
r Man
r Manu
r Manu
r Manu
r Manus
r Manus
r Manus
r Manuso
r Manusc
r Manusci
r Manuscr
r Manuscri
r Manuscrij
r Manuscrip
r Manuscrip
r Manuscript

**NIH-PA Author Manuscript** 

_	
2	
=	
- <del></del>	
_0	
~	
<u> </u>	
<b>----</b>	
<u> </u>	
<u> </u>	
<	
0	
<b>~</b>	
7	
5	
Š	
4	
÷.	
¥	

Study		Popul	ation	u	Role-Phys. M (SD)	Physical Func. M (SD)	Vitality M (SD)	Social Func. M (SD)	Bodily Pain M (SD)	Role-Emo. M (SD)	Ment. Health M (SD)	Gen. Health M (SD)
		ISF		57	60.7 (37.2)	77.5 (18.9)	37.3 (18.5)	74.2 (19.6)	59.7 (20.0)	76.5 (33.5)	74.6 (14.0)	70.1 (13.6)
		Contro	1	64	88.8 (25.0)	89.7 (13.2)	72.3 (13.0)	94.8 (10.6)	77.9 (16.0)	96.1 (13.8)	87.5 (9.0)	85.2 (13.3)
Scheeres, Wensin,	g, Severens,	CFS-A	II	263	NR	52.3 (22.6)	NR	NR	NR	NR	NR	NR
Adang, & Bleijen	berg (2008) <sup>d</sup>	CFS-N	1HC	114	NR	52.4 (23.0)	NR	NR	NR	NR	NR	NR
		CFS-E	CCF	149	NR	53.2 (22.4)	NR	NR	NR	NR	NR	NR
Taillefer, Kirmaye	ər, Robbins, &	CFS		45	10.8 (22.5)	49.6 (25.0)	22.7 (18.7)	38.1 (25.0)	45.3 (24.4)	58.3 (45.0)	65.8 (20.4)	38.8 (21.3)
Lasry (2002)		Multip	de Sclerosis	40	33.6 (42.4)	42.8 (33.5)	38.8 (21.6)	65.8 (27.1)	65.1 (32.6)	66.7 (37.2)	67.7 (15.3)	47.7 (24.8)
Study	Population	=	Role-Phys. M (95% CI)	Physical F M (95% C	unc. Vita I) M (	dity Sc 95% CI) M	ocial Func. [ (95% CI)	Bodily Pain M (95% CI)	Role-Emc M (95% (	e. Me CI) M(	nt. Health 95% CI)	Gen. Health M (95% CI)
Herrell et al.	CF	119	21 (16–26)	49 (46–53)	22 (	19–35) 43	3 (40-47)	40 (36-45)	66 (59–72	() 62 (	(29–65)	36 (33–40)
$(2002)^{\uparrow e}$	Twin Control	119	89 (83–93)	90 (86–94)	65 (	62–68) 88	3 (84–91)	74 (70–78)	87 (80–93	) 75 (	(72–78)	81 (78–84)
	CFS-Exclusion	74	19 (14–25)	52 (47–57)	21 (	17–25) 44	t (40–48)	40 (36-45)	69 (61–77	) 62 (	(58–63)	35 (32–39)
	Twin Control	74	90 (84–95)	92 (88–97)	70 (	66–73) 91	l (87–95)	76 (71–81)	90 (82–98	17 (1	(74–81)	85 (81–89)
	CFS	22	13 (4–22)	45 (38–53)	16 (	10–22) 44	t (35–52)	36 (26–46)	58 (41–74	() 25 (	(47–62)	32 (26–38)
	Twin Control	22	(80-08) 68	95 (87–100	) 72 (	66–78) 90	(82–99)	79 (69–89)	91 (75–10	0) 80 (	(72–87)	85 (85–91)
Nater et al.	CFS	43	18.0 (9.3–26.8)	53.3 (46.6-	-59.9) 18.6	(14.8–22.5) 50	).0 (43.0–57.0)	41.7 (36.9-46.5	) 55.8 (42.8		4 (60.7–72.1)	51.2 (44.9–57.5)
$(2006)^{T}$	Control	60	88.8 (82.3–95.2)	89.7 (86.2-	-93.1) 72.3	(689–75.6) 94	1.8 (92.0–97.5)	77.9 (73.7–82.0	) 96.1 (92.5	78 (7.99)	5 (85.2–89.8)	85.2 (81.8–88.7)
Wells (2009)	CFS Pet	98	13.4 (8.0–18.8)	30.8 (25.9-	-35.8) 20.1	(16.7–23.6) 31	1.8 (26.6–37.1)	37.0 (30.9-43.2	) 67.9 (58.8	-76.9) 64.	t (60.0–68.9)	30.4 (26.4–34.3)
	CFS No Pet	70	12.3 (5.3–19.3)	32.0 (26.6-	-37.5) 18.8	(15.0–22.6) 33	3.5 (28.0–39.0)	38.3 (32.2-44.4	) 66.7 (55.8	-77.5) 62.8	8 (57.6–68.1)	26.4 (22.5–30.4)
	Combined	168	12.9 (8.7–17.2)	31.3 (27.7-	-35.0) 19.6	(17.0–22.1) 32	2.5 (28.8–36.3)	37.6 (33.2–41.9	) 67.4 (60.5	-74.2) 63.8	8 (60.4–67.1)	28.7 (25.9–31.6)
Notes:												
NR = Not Reported Symptoms or Fatigu	; CI = Confidence i ie	Interval	t; Psy = Comorbid ps	ychiatric coi	ndition; Psy I	Exclusion = Does	not meet criteria	for CFS due to e	clusionary ps	ychiatric conc	lition; ISF = Inst	ıfficient
$^{ au}$ Study included in :	analysis of differen	tce scor	es									

.

<sup>d</sup>This study evaluated the Reeves et al. (2005) empiric case definition where MDD = Major Depressive Disorder; MDD/CFS = Patients with MDD classified as CFS using this case definition. b This study explored post-exertional malaise where Pre-Exerc. = Assessment before exercise; Post-Exerc. = Assessment after exercise; 24 Hrs-Post = Assessment 24 hours after exercise. <sup>c</sup> This study compares the SF-36 scores of native Dutch speaking participants with native French speaking participants. \* Study using the Reeves et al. (2005) empiric case definition

Jason et al.

<sup>d</sup>The MHC group was participants with CFS recruited from a community mental health center and the ECCF group was participants with CFS recruited from the Nijmegen Expert Centre for Chronic Fatigue.

<sup>e</sup>This study looked at pairs of monozygotic twins where one twin was sick, meeting a diagnosis of: chronic fatigue (CF; ≥ 6 months fatigue); CFS-Excl. (≥ 6 months fatigue and atleast four minor symptoms) but exclusionary condition; or CFS ( $\geq 6$  months fatigue and at least four minor symptoms) with no exclusionary conditions; and the control was his or her healthy twin.

 $f_{
m This}$  study looked at differences in people with CFS that were pet owners versus non-pet owners.

Jason et al.

# Table 2

AUC Values, Standard Errors (SE), and Confidence Intervals (CI) for Community-Based and Tertiary Care Samples

SF-36 Subscale	Commu	mity-Ba	ased Sample	Tertia	ry Ca	re Sample
	AUC	SE	95% CI <sup>†</sup>	AUC	SE	95% CI <sup>†</sup>
Vitality	88.	.04	.81 – .96	.91	.03	.85 – .97
Social Functioning	.87	.04	.79 – .95	.87	.04	.79 – .94
Role-Physical	.86	.04	.77 – .94	.91	.03	.84 – .97
Bodily Pain	.85	.04	.77 – .94	.86	.04	.79 – .93
Physical Functioning	.84	.05	.75 – .93	.87	.04	.80 – .94
General Health	.80	.05	.7090	.91	.03	.86 – .97
Mental Health	.75	.06	.63 – .86	.71	.05	.61 – .80
Role-Emotional	.67	.07	.5480	.63	.05	.53 – .73

<sup> $\prime$ </sup> Confidence intervals not including .5 are significant at the p < .05 level